epr-method (2003) - IAEA Publications - International Atomic Energy ...
epr-method (2003) - IAEA Publications - International Atomic Energy ...
epr-method (2003) - IAEA Publications - International Atomic Energy ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
BENCHMARKS FOR INHALATION<br />
AI.5 Selection of proper D 2 values requires knowledge of the possible deterministic effects of<br />
internally deposited radionuclides. In contrast to deterministic effects from external radiation<br />
sources, there is very little information available on deterministic effects in human subjects from<br />
intake of radionuclides. A meeting of consultants was held to review the use of data on<br />
deterministic effects in laboratory animals to independently verify, in benchmark calculations,<br />
some of the D 2 values calculated. Models were used for deterministic health effects that were based<br />
on effects seen in life-span studies in dogs and rats [56,57]. The consultants focused on radiation<br />
pneumonitis/pulmonary fibrosis as the deterministic effect of interest for inhaled radionuclides<br />
because it would be the most likely cause of a permanent injury that decreases in the quality of life.<br />
Benchmark calculations were made for a number of r<strong>epr</strong>esentative radionuclides using basic<br />
principles from these models and doses calculated to the alveolar-interstitial (AI) region of the<br />
lung. The calculations estimated, assuming an intake faction of 10 -4 , the activity (TBq) that would<br />
result in an approximate threshold (5%) for morbidity from radiation pneumonitis/pulmonary<br />
fibrosis. Table AI-II compares these benchmark D 2 values with the D 2 values from Table A8-I.<br />
Generally speaking, there is good agreement between the two sets of D 2 values for alpha- and beta,<br />
gamma-emitting radionuclides.<br />
AI.6 A second set of calculations examined whether the criterion of 6 Gy to the lung in 2 days is<br />
an appropriate way to consider the chronic irradiation patterns for various beta, gamma-emitting<br />
radionuclides in the AI region. This was needed because of the broad range of effective retention<br />
and physical half-lives that might be involved. The consultants looked at several long-lived beta,<br />
gamma-emitting radionuclides. A different dose criterion, a cumulative absorbed dose of 75 Gy to<br />
the AI region in 1 year, was considered because it could lead to an approximate 5% morbidity level<br />
from radiation pneumonitis/pulmonary fibrosis. Table AI-III gives the results of these benchmark<br />
D 2 values compared with the Table A8-I values. Again, the two sets of numbers agree within<br />
factors of 2 or 3.<br />
AI.7 These benchmark calculations indicate that the Table A8-I values that have been examined<br />
are consistent within factors of 1 to 5 of values derived from the best currently available models on<br />
deterministic health effects in the lung. In most cases the D 2 values in Table A8-I appear to be<br />
slightly conservative.<br />
TABLE AI-II. COMPARISON OF TABLE A8-I D 2 VALUES WITH VALUES<br />
CALCULATED FROM MODELS FOR RADIATION PNEUMONITIS/PULMONARY<br />
FIBROSIS (AI, TYPE S).<br />
Nuclide Table A8-I Benchmark<br />
Beta, Gamma Emitters<br />
Sr-90 1 4.7<br />
Ce-144 9 63<br />
Cs-134 30 30<br />
Co-60 30 25<br />
Alpha Emitters<br />
Pu-238 0.06 0.08<br />
Pu-239 0.06 0.08<br />
Pu-240 0.06 0.08<br />
Am-241 0.06 0.08<br />
264